K Clint Cary1, Janet E Cowan2, Melissa Sanford2, Katsuto Shinohara2, Nannette Perez2, June M Chan2, Maxwell V Meng2, Peter R Carroll2. 1. Department of Urology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: clintcary20@gmail.com. 2. Department of Urology, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Abstract
BACKGROUND: A better understanding of the independent predictors of disease progression for prostate cancer (PCa) patients is needed to improve the selection of ideal candidates for active surveillance (AS) and refine the surveillance regimen. OBJECTIVE: To examine the association of clinical and pathologic characteristics, as well as patterns of surveillance biopsy results, with the risk of progression in men on AS. DESIGN, SETTING, AND PARTICIPANTS: The retrospective study consisted of men with PCa who were on AS in the prospectively maintained University of California, San Francisco, institutional database from 1996 to 2011. Strict criteria for AS were prostate-specific antigen (PSA) ≤10 ng/ml, clinical stage T1 or T2, biopsy Gleason grade 6, <33% positive cores, and <50% tumor in any single core. Men were then categorized based on results of their confirmatory surveillance biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease progression was defined as an increase in Gleason grade and/or biopsy volume beyond prespecified cut points. Serial biopsy patterns over the course of surveillance were stratified by confirmatory biopsy findings: negative, positive without progression, and positive with progression. Multivariable logistic regression models were used to evaluate predictors of progression during AS. RESULTS AND LIMITATIONS: A total of 465 men met inclusion criteria (median follow-up: 51 mo). Of these men, 23% had negative confirmatory biopsies. Only 3% of the men (1 of 30) progressed by the fourth surveillance biopsy following a biopsy pattern of negative confirmatory and negative third biopsy findings. Negative confirmatory biopsy and lower PSA density (both p<0.01) were independently associated with decreased odds of biopsy progression at 3 yr. The main limitation of this study is its observational nature. CONCLUSIONS: The patterns of surveillance biopsy results yield additional important information in AS. Negative confirmatory biopsy and PSA density are important independent predictors of progression on AS and may be used to better counsel men opting for AS.
BACKGROUND: A better understanding of the independent predictors of disease progression for prostate cancer (PCa) patients is needed to improve the selection of ideal candidates for active surveillance (AS) and refine the surveillance regimen. OBJECTIVE: To examine the association of clinical and pathologic characteristics, as well as patterns of surveillance biopsy results, with the risk of progression in men on AS. DESIGN, SETTING, AND PARTICIPANTS: The retrospective study consisted of men with PCa who were on AS in the prospectively maintained University of California, San Francisco, institutional database from 1996 to 2011. Strict criteria for AS were prostate-specific antigen (PSA) ≤10 ng/ml, clinical stage T1 or T2, biopsy Gleason grade 6, <33% positive cores, and <50% tumor in any single core. Men were then categorized based on results of their confirmatory surveillance biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease progression was defined as an increase in Gleason grade and/or biopsy volume beyond prespecified cut points. Serial biopsy patterns over the course of surveillance were stratified by confirmatory biopsy findings: negative, positive without progression, and positive with progression. Multivariable logistic regression models were used to evaluate predictors of progression during AS. RESULTS AND LIMITATIONS: A total of 465 men met inclusion criteria (median follow-up: 51 mo). Of these men, 23% had negative confirmatory biopsies. Only 3% of the men (1 of 30) progressed by the fourth surveillance biopsy following a biopsy pattern of negative confirmatory and negative third biopsy findings. Negative confirmatory biopsy and lower PSA density (both p<0.01) were independently associated with decreased odds of biopsy progression at 3 yr. The main limitation of this study is its observational nature. CONCLUSIONS: The patterns of surveillance biopsy results yield additional important information in AS. Negative confirmatory biopsy and PSA density are important independent predictors of progression on AS and may be used to better counsel men opting for AS.
Authors: Jonathan B Bloom; Graham R Hale; Samuel A Gold; Kareem N Rayn; Clayton Smith; Sherif Mehralivand; Marcin Czarniecki; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: Haley Hieronymus; Nikolaus Schultz; Anuradha Gopalan; Brett S Carver; Matthew T Chang; Yonghong Xiao; Adriana Heguy; Kety Huberman; Melanie Bernstein; Melissa Assel; Rajmohan Murali; Andrew Vickers; Peter T Scardino; Chris Sander; Victor Reuter; Barry S Taylor; Charles L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Stacy Loeb; Sophie M Bruinsma; Joseph Nicholson; Alberto Briganti; Tom Pickles; Yoshiyuki Kakehi; Sigrid V Carlsson; Monique J Roobol Journal: Eur Urol Date: 2014-10-31 Impact factor: 20.096
Authors: Michael S Leapman; Janet E Cowan; Hao G Nguyen; Katsuto K Shinohara; Nannette Perez; Matthew R Cooperberg; William J Catalona; Peter R Carroll Journal: J Clin Oncol Date: 2017-03-27 Impact factor: 44.544
Authors: François Audenet; Emily A Vertosick; Samson W Fine; Daniel D Sjoberg; Andrew J Vickers; Victor E Reuter; James A Eastham; Peter T Scardino; Karim A Touijer Journal: J Urol Date: 2017-10-10 Impact factor: 7.450
Authors: Christopher B Anderson; Amy L Tin; Daniel D Sjoberg; John P Mulhall; Jaspreet Sandhu; Karim Touijer; Vincent P Laudone; James A Eastham; Peter T Scardino; Behfar Ehdaie Journal: BJU Int Date: 2015-07-20 Impact factor: 5.588
Authors: J P Radtke; T H Kuru; D Bonekamp; M T Freitag; M B Wolf; C D Alt; G Hatiboglu; S Boxler; S Pahernik; W Roth; M C Roethke; H P Schlemmer; M Hohenfellner; B A Hadaschik Journal: Prostate Cancer Prostatic Dis Date: 2016-05-17 Impact factor: 5.554